Clinical Effectiveness of WAL801CL (Epinastine Hydrochloride) in Pruritic Dermatosis

Abstract

The effectiveness of WAL801CL (Epinastinehydrochloride) was evaluated in a cooperativestudy by 10 institutions. 208 patients withpruritic dermatosis were selected for thisstudy, and an open label study was performedby using oral administration of 20mg tableta day. The drug effect and side effects wereanalyzed in 207 out of 208 patients, and the following results were obtained:
1) The final improvement rating of itchingwas 84.8% for eczema-dermatitis group, 88.5% for prurigo group, 89.7% for urticaria group, 90.3% for pruritus cutaneus and 84.6% forpsoriasis vulgaris.
2) The final rating of general improvementwas 70.7% for eczema-dermatitis group, 68.8%for prurigo group, 81.3% for urticaria group, 78.1% for pruritus cutaneus and 64.5% forpsoriasis vulgaris.
3)The safety of the drug was not questionedat all in 96.6% of patients.
4) The rate of overall usefulness was 68.3% for eczema-dermatitis group, 63.6% forprurigo group, 83.3% for urticaria group, 75.0% for pruritus cutaneus and 61.3% forpsoriasis vulgaris.
These results confirmed that WAL801CL was effective, safe and useful for pruriticdermatosis.